Newborn screening for cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 9, Issue 5, 2015, Pages 619-631

  Gonska, Tanja ^a,b   Ratjen, Felix ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cystic fibrosis; Nbs; Positive screened newborns with inconclusive diagnosis

Indexed keywords

ALBUMIN; IMMUNE REACTIVE TRYPSINOGEN; TRYPSINOGEN; UNCLASSIFIED DRUG;

CFTR GENE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA SEQUENCE; FALSE NEGATIVE RESULT; GENE; GENE MUTATION; GENETIC BACKGROUND; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMAN; LUNG FIBROSIS; METABOLIC DISORDER; NEWBORN; NEWBORN SCREENING; NEXT GENERATION SEQUENCING; NUTRITIONAL STATUS; PANCREAS FUNCTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SWEAT TEST; COMPLICATION; CYSTIC FIBROSIS; STANDARDS;

CYSTIC FIBROSIS; GENETIC TESTING; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING;

EID: 84964370107     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1085804     Document Type: Review

References (86)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989; 245(4922):1066-73
2. The metabolic and molecular basis of inherited disease, in cystic fibrosis. Welsh M, Scriver CR, Beaudet AL, et al.Scriver CR. editors. McGraw-Hill; New York: 2001. p. 5121-88
3. Ratjen F, Rowe SM, Goss CL, et al. Cystic Fibrosis. Nat Rev Dis Prim, 2015
4. Canada. Report of the Canadian Patient Data Registry 2013
5. Chopra R, Paul L, Manickam R, et al. Efficacy and adverse effects of drugs used to treat adult cystic fibrosis. Expert Opin Drug Saf 2015;1-11
6. Chevreul K, Berg Brigham K, Michel M, et al. Costs and health-related quality of life of patients with cystic fibrosis and their carers in France. J Cyst Fibros 2015
7. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-72
8. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. Lancet Respir Med 2014;2(7):527-38
9. FDA Approves ORKAMBI-(lumacaftor/ivacaftor)-the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation. Available from: http://investors.vrtx.com/releasedetail.cfm? releaseid=920512
10. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180(2):146-52
11. Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007;175(9):943-50
12. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368(21): 1963-70
13. Report of a WHO Scientific Group. Screening for inborn errors of metabolism. World Health Organ Tech Rep Ser 1968;401:1-57
14. Anne Andermann IB. Sylvie Beauchamp, Ve-ronique De-r, Revisiting Wilson and Jungner in the genomic age: A review of screening criteria over the past 40 years. Bulletin of the World Health Organization 2008;86(4):241-320
15. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979; 1(8114):472-4
16. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23(3):545-9
17. Rock MJ, Hoffman G, Laessig RH, et al. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. J Pediatr 2005;147(3 Suppl):S73-7
18. Lagoe E, Labella S, Arnold G, et al. Cystic fibrosis newborn screening: A pilot study to maximize carrier screening. Genet Test 2005;9(3):255-60
19. Merelle ME, Schouten JP, Gerritsen J, et al. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001;18(2):306-15
20. Dankert-Roelse JE, te Meerman GJ. Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre. Thorax 1995;50:7:712-18
21. Waters DL, Wilcken B, Irwing L, et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999;80(1):F1-7
22. McKay KO, Waters DL, Gaskin KJ. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in new South Wales. J Pediatr 2005;147(3 Suppl): S47-50
23. Mastella G, Zanolla L, Castellani C, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology 2001;1(5):531-7
24. Wang SS, O'Leary LA, Fitzsimmons SC, et al. The impact of early cystic fibrosis diagnosis on pulmonary function in children. J Pediatr 2002;141(6):804-10
25. Lai HJ, Cheng Y, Cho H, et al. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol 2004; 159(6):537-46
26. Grosse SD, Rosenfeld M, Devine OJ, et al. Potential impact of newborn screening for cystic fibrosis on child survival: A systematic review and analysis. J Pediatr 2006;149(3): 362-6
27. Hammond KB, Abman SH, Sokol RJ, et al. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med 1991; 325(11):769-74
28. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997;337(14):963-9
29. Shwachman H, Mahmoodian A. Pilocarpine iontophoresis sweat testing results of seven years' experience. Bibl Paediatr 1967;86: 158-82
30. Campbell PW, White TB 3rd. Newborn screening for cystic fibrosis: An opportunity to improve care and outcomes. J Pediatr 2005;147(3 Suppl):S2-5
31. Mayell SJ, Munck A, Craig JV, et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009;8(1):71-8
32. Cystic Fibrosis F, Borowitz D, Parad RB, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009;155(6 Suppl): S106-16
33. Assael BM, Castellani C, Ocampo MB, et al. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol 2002;156(5):397-401
34. Wilcken B, Brown AR, Urwin R, et al. Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants. J Pediatr 1983;102(3):383-7
35. Massie RJ, Wilcken B, Van Asperen P, et al. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr 2000; 137(2):214-20
36. Sontag MK, Hammond KB, Zielenski J, et al. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 2005; 147(3 Suppl):S83-8
37. Hale JE, Parad RB, Dorkin HL, et al. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis 2010; 33(Suppl 2):S255-61
38. Lim MT, Wallis C, Price JF, et al. Diagnosis of cystic fibrosis in London and South East England before and after the introduction of newborn screening. Arch Dis Child 2014;99(3):197-202
39. Edminson PD, Michalsen H, Aagenaes O, et al. Screening for cystic fibrosis among newborns in Norway by measurement of serum/plasma trypsin-like immunoreactivity. Results of a 2 1/2-year pilot project. Scand J Gastroenterol Suppl 1988;143:13-18
40. Pollak A, Kasper DC. Austrian Newborn Screening Program: A perspective of five decades. J Perinat Med 2014;42(2):151-8
41. Audrezet MP, Munck A, Scotet V, et al. Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy. Genet Med 2015;17(2):108-16
42. Southern KW, Munck A, Pollitt R, et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 2007;6(1): 57-65
43. Castellani C, Southern KW, Brownlee K, et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009;8(3):153-73
44. Rodrigues R, Magalhaes PK, Fernandes MI, et al. Neonatal screening for cystic fibrosis in Sao Paulo State, Brazil: A pilot study. Braz J Med Biol Res 2009;42(10):973-8
45. Wagener JS, Zemanick ET, Sontag MK. Newborn screening for cystic fibrosis. Curr Opin Pediatr 2012;24(3):329-35
46. Rosenthal M. Newborn screening for cystic fibrosis: The motion against-voices in the wilderness. Paediatr Respir Rev 2008;9(4): 295-300
47. McKay K, Wilcken B. Newborn screening for cystic fibrosis offers an advantage over symptomatic diagnosis for the long term benefit of patients: The motion for. Paediatr Respir Rev 2008;9(4):290-4
48. Southern KW, Me-relle MM, Dankert-Roelse JE, et al. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev 2009(1):CD001402
49. Koscik RL, Farrell PM, Kosorok MR, et al. Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics 2004;113(6): 1549-58
50. Farrell PM, Shen G, Splaingard M, et al. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997; 100(5):E2
51. Sanders DB, Li Z, Laxova A, et al. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc 2014;11(1):63-72
52. Chatfield S, Owen G, Ryley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: Clinical assessment after five years of screening. Arch Dis Child 1991;66(1 Spec No):29-33
53. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 2005;147(3 Suppl):S37-41
54. Sims EJ, McCormick J, Mehta G, et al. Neonatal screening for cystic fibrosis is beneficial even in the context of modern treatment. J Pediatr 2005;147(3 Suppl): S42-6
55. Doull IJ, Ryley HC, Weller P, et al. Cystic fibrosis-related deaths in infancy and the effect of newborn screening. Pediatr Pulmonol 2001;31(5):363-6
56. Prosser R, Owen H, Bull F, et al. Screening for cystic fibrosis by examination of meconium. Arch Dis Child 1974;49(8): 597-601
57. Kloosterboer M, Hoffman G, Rock M, et al. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 2009;123(2):e338-46
58. Massie RJ, Curnow L, Glazner J, et al. Lessons learned from 20 years of newborn screening for cystic fibrosis. Med J Aust 2012;196(1):67-70
59. Sommerburg O, Lindner M, Muckenthaler M, et al. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 2010; 33(Suppl 2):S263-71
60. Sommerburg O, Hammermann J, Lindner M, et al. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. Pediatr Pulmonol 2015. [Epub ahead of print]
61. Arnold C. New cystic fibrosis genetic tests bring hope and dilemmas. Lancet Respir Med 2014;2(1):30
62. Cystic fibrosis mutation database. Available from: www.genet.sickkids.on.ca
63. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013; Epub ahead of print
64. Ooi CY, Dupuis A, Ellis L, et al. Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? Thorax 2014;69(3):254-60
65. Prach L, Koepke R, Kharrazi M, et al. Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California. J Mol Diagn 2013; 15(5):710-22
66. Salinas DB, Sosnay PR, Azen C, et al. Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants. J Cyst Fibros 2015. [Epub ahead of print]
67. Thauvin-Robinet C, Munck A, Huet F, et al. The very low penetrance of cystic fibrosis for the R117H mutation: A reappraisal for genetic counselling and newborn screening. J Med Genet 2009; 46(11):752-8
68. Sontag MK, Wright D, Beebe J, et al. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA. J Pediatr 2009;155(5):618-22
69. Sontag MK, Corey M, Hokanson JE, et al. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J Pediatr 2006;149(5):650-7
70. Ulph F, Cullinan T, Qureshi N, et al. Parents' responses to receiving sickle cell or cystic fibrosis carrier results for their child following newborn screening. Eur J Hum Genet 2015;23(4):459-65
71. Tluczek A, Orland KM, Cavanagh L. Psychosocial consequences of false-positive newborn screens for cystic fibrosis. Qual Health Res 2011;21(2):174-86
72. Tluczek A, Laxova A, Grieve A, et al. Long-term follow-up of cystic fibrosis newborn screening: psychosocial functioning of adolescents and young adults. J Cyst Fibros 2014;13(2):227-34
73. Castellani C, Picci L, Scarpa M, et al. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. Am J Med Genet A 2005; 135(2):142-4
74. Comeau AM, Larson C, Eaton RB. Integration of new genetic diseases into statewide newborn screening: New England experience. Am J Med Genet C Semin Med Genet 2004;125C(1):35-41
75. Parad RB, Comeau AM. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J Pediatr 2005;147(3 Suppl):S78-82
76. Castellani C, Picci L, Tamanini A, et al. Association between carrier screening and incidence of cystic fibrosis. JAMA 2009; 302(23):2573-9
77. Munck A, Mayell SJ, Winters V, et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 2015. [Epub ahead of print]
78. Ooi CY, Dupuis A, Ellis L, et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language? Thorax 2012; 67(7):618-24
79. Gonska T, Choi P, Stephenson A, et al. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. Chest 2012; 142(4):996-1004
80. Ren CL, Fink AK, Petren K, et al. Outcomes of Infants With Indeterminate Diagnosis Detected by Cystic Fibrosis Newborn Screening. Pediatrics 2015; Epub ahead of print
81. Ooi CY, Castellani C, Keenan K, et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 2015; Epub ahead of print
82. Narzi L, Ferraguti G, Stamato A, et al. Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up. Clin Genet 2007;72(1):39-46
83. Massie J, Gillam L. Uncertain diagnosis after newborn screening for cystic fibrosis: An ethics-based approach to a clinical dilemma. Pediatr Pulmonol 2014;49(1):1-7
84. Groves T, Robinson P, Wiley V, et al. Long-Term Outcomes of Children with Intermediate Sweat Chloride Values in Infancy. J Pediatr 2015. [Epub ahead of print]
85. Ren CL, Desai H, Platt M, et al. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Pediatr Pulmonol 2011;46(11):1079-84
86. Perobelli S, Zanolla L, Tamanini A, et al. Inconclusive cystic fibrosis neonatal screening results: long-term psychosocial effects on parents. Acta Paediatr 2009; 98(12):1927-34